Orchid - Geht da doch noch was? - 500 Beiträge pro Seite

[suncomesout]

OHS scheint aus seinem Dornröschenschlaf zu erwachen:

FOR IMMEDIATE RELEASE

Orchid BioSciences, Inc.
[phone]

Orchid Cellmark
Mark D. Stolorow
Executive Director




ORCHID CELLMARK LAUNCHES RAPID FORENSIC DNA ANALYSIS SERVICE

-- New “DNA Express Service” Designed for Local Law Enforcement Agencies Delivers Accurate DNA Results in Just Five Days --


GERMANTOWN, MD., Jan. 15, 2003 - Orchid Cellmark, a leader in private forensic DNA profiling, announced today the launch of a new “DNA Express Service” for local law enforcement agencies. The new premium service delivers forensic DNA results for “no suspect” and other criminal cases within five business days, compared to the standard average turn-around time of four to five weeks for routine casework. No-suspect cases are unsolved crimes in which an alleged perpetrator has not yet been identified. Many state crime labs face up to twelve-month backlogs in analyzing DNA evidence for these no-suspect cases.

The new DNA Express Service is designed to enable local law enforcement agencies to work directly with Orchid Cellmark to obtain rapid, accurate DNA analysis in no-suspect cases and conventional criminal cases with suspects. Orchid Cellmark works with local agencies to expedite the entire process, from transporting crime scene specimens to Orchid Cellmark’s laboratories to conducting the analysis and reporting back results in approximately one week.

“With the resource of convicted offender DNA databases now available in most states, law enforcement can no longer accept lengthy delays in processing no-suspect DNA evidence,” said Mark Stolorow, executive director of Orchid Cellmark. “We believe that our DNA Express Service, which has a faster turn-around than any other premium service offered in the industry, provides local law enforcement officials with a valuable new option that will enable them to analyze no-suspect DNA evidence in a more timely and efficient manner.”

Statistics show that many offenders who have been convicted of felonies such as rape are likely to commit subsequent offenses, so DNA databases of convicted offenders are becoming a potent tool for solving crimes. By more rapidly processing no suspect DNA evidence, local law enforcement agencies are able to solve more of these crimes and to do so more quickly, thereby also reducing the chance that repeat offenders will go on to commit additional crimes during the time that they are not apprehended and remain at large.

Many state crime laboratories continue to have a massive accumulation of unanalyzed DNA evidence, with the total nationwide backlog estimated at up to 500,000 cases. This backlog hampers the resolution of unsolved crimes. With a world-class reputation for conducting DNA forensic casework, three forensic DNA facilities accredited by ASCLD-LAB, and procedures and processes in place to ensure rapid testing turn around, Orchid Cellmark intends its DNA Express Service to become a valuable new resource for local law enforcement agencies demanding quick, accurate DNA analysis of no-suspect cases.

About Orchid Cellmark
Orchid Cellmark, the forensic strategic business unit of Orchid BioSciences, Inc., is a leader in private forensic DNA analysis. Orchid Cellmark has an international network of four forensic testing laboratories in the U.S. and U.K., making it the largest private DNA forensic testing service provider in the world. Orchid Cellmark provides a full range of high quality, customized forensic DNA testing services, including identification of victims of accidents and disasters, criminal casework analysis and expert testimony, convicted offender DNA databasing, no-suspect casework for government law enforcement laboratories, and DNA testing and consultative services for the defense bar as well as for the prosecution. Orchid Cellmark, which has conducted DNA testing for many notable forensic investigations, uses a variety of genetic analysis methods for its forensic DNA studies and is a leader in developing improved technologies for genetic analysis. More information on Orchid Cellmark can be found at www.orchidcellmark.com.

[js200]

http://www.investtech.com/nasdaq/ana/orch.htm

JS200

[js200]

05/02/2003 (07:00 ET) Orchid BioSciences to Host Conference Call to Announce First Quarter 2003 Financial Results - PR Newswire
05/01/2003 (11:13 ET) VOLUME(o): ORCH Volume 10% > 20-adsv, Stock EVEN - Knobias
04/30/2003 (17:37 ET) New DEF 14A just released for ORCH - Edgar
04/30/2003 (14:41 ET) VOLUME(+): ORCH Volume 75% > 20-adsv, Stock +4.65% - Knobias
04/25/2003 (14:26 ET) VOLUME(-): ORCH Volume 51% > 20-adsv, Stock -11.11% - Knobias

JS200

[js200]

Orchid BioSciences to Host Conference Call to Announce First Quarter 2003 Financial Results

Friday , May 02, 2003 07:00 ET

PRINCETON, N.J., May 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) will release its first quarter 2003 financial results before the U.S. financial markets open on Thursday, May 8, 2003 and is hosting a conference call that also will be broadcast live over the Internet that day at 10:00 a.m. ET. Participating members of Orchid senior management include George Poste, D.V.M., Ph.D., chairman, and Andrew Savadelis, chief financial officer. Management will discuss financial results for the first quarter as well as Orchid`s recent operating highlights. A question-and-answer session will follow management`s discussion.


What: Orchid BioSciences, Inc. First Quarter 2003 Financial Results
Conference Call

When: Thursday, May 8, 2003, 10:00 a.m. ET

How: The dial-in number is 1-973-694-6836 for domestic and
international callers.


A live Webcast of the conference call and a replay will also be available via the Investor Relations section of the company`s website at www.orchid.com. All interested parties are encouraged to listen to the live conference call or the live or archived Webcast.

About Orchid BioSciences

Orchid BioSciences is the leading provider of services and products for profiling genetic uniqueness. Orchid`s interlocking strategic business units address distinctive markets that together represent a unique balance of established, predictable growth, such as forensic and paternity DNA testing, and large upside potential, like pharmacogenetics-based personalized healthcare. All leverage Orchid`s network of accredited genotyping laboratories, its leading technologies and its expertise in genetic analysis. Orchid provides identity genomics testing for forensics and paternity through Orchid Cellmark and Orchid GeneScreen, and also provides public health genotyping services. Orchid GeneShield is developing pharmacogenetics-based programs designed to accelerate the adoption of personalized healthcare. More information on Orchid can be found at www.orchid.com.

SOURCE Orchid BioSciences, Inc.


CONTACT: Tracy J. Henrikson, Director, Corporate Communications, Orchid
BioSciences, [phone]

URL: http://www.orchid.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: New Jersey
INDUSTRY KEYWORD: HEA
MTC
BIO
SUBJECT CODE: MAV
CCA

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/02/2003 (07:00 ET) Orchid BioSciences to Host Conference Call to Announce First Quarter 2003 Financial Results - PR Newswire



05/01/2003 (11:13 ET) VOLUME(o): ORCH Volume 10% > 20-adsv, Stock EVEN - Knobias



04/30/2003 (17:37 ET) New DEF 14A just released for ORCH - Edgar



04/30/2003 (14:41 ET) VOLUME(+): ORCH Volume 75% > 20-adsv, Stock +4.65% - Knobias



04/25/2003 (14:26 ET) VOLUME(-): ORCH Volume 51% > 20-adsv, Stock -11.11% - Knobias



04/24/2003 (11:36 ET) VOLUME(+): ORCH Volume 48% > 20-adsv, Stock +13.16% - Knobias



04/15/2003 (11:30 ET) Orchid BioSciences Shareholders Authorize Reverse Stock Split - PR Newswire



04/15/2003 (07:02 ET) DEF 14A: ORCH Proxy Vote; Authorize Reverse Stock Split - Knobias

JS200

[js200]

Orchid BioSciences Shareholders Authorize Reverse Stock Split

Tuesday , April 15, 2003 11:30 ET

PRINCETON, N.J., Apr 15, 2003 /PRNewswire-FirstCall via COMTEX/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced today that its shareholders have approved the authorization of a reverse split of the Company`s common stock.

The resolution, approved by Orchid`s shareholders at the Special Meeting of Shareholders held today, authorizes the Board of Directors to amend the Company`s Restated Certificate of Incorporation to implement a reverse split of the issued and outstanding shares of Orchid`s common stock. As a result of the approval obtained today, Orchid`s Board of Directors has discretionary authority to implement a reverse stock split ranging from 1-for-3 shares to 1-for-7 shares prior to the Company`s Annual Meeting of Shareholders, which is scheduled to be held on June 12, 2003.

Orchid received a notice from Nasdaq in January 2003 indicating that the Company failed to comply with the $1.00 minimum bid price required for continued listing by Marketplace Rule 4450(a)(5) and that its common stock was subject to delisting from the Nasdaq National Market. Orchid subsequently made a formal appeal to maintain the Company`s listing on the Nasdaq National Market and a hearing was held before a Nasdaq Listing Qualifications Panel in February 2003. A Nasdaq Listing Qualifications Panel determined in March 2003 that it will continue to list the Company`s common stock on the Nasdaq National Market through June 24, 2003. This additional 90-day period provides Orchid with an opportunity to continue to make progress in strengthening its business and its financial position and to implement the reverse stock split authorized by its stockholders today, in order to regain compliance with the $1.00 minimum bid price requirement.

There can be no assurance that the Nasdaq Qualifications Panel will decide to allow Orchid to remain listed or that Orchid`s actions will prevent the delisting of its common stock from the Nasdaq National Market after June 24, 2003.

About Orchid BioSciences

Orchid BioSciences is the leading provider of services and products for profiling genetic uniqueness. Orchid`s interlocking strategic business units address distinctive markets that together represent a unique balance of established, predictable growth, such as forensic and paternity DNA testing, and large upside potential, like pharmacogenetics-based personalized healthcare. All leverage Orchid`s network of accredited genotyping laboratories, its leading technologies and its expertise in genetic analysis. Orchid provides identity genomics testing for forensics and paternity through Orchid Cellmark and Orchid GeneScreen, and also provides public health genotyping services. Orchid GeneShield is developing pharmacogenetics-based programs designed to accelerate the adoption of personalized healthcare. More information on Orchid can be found at www.orchid.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Orchid`s belief that pharmacogenetics-based personalized healthcare represents a market with large upside potential for its interlocking strategic business units. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid products and services, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. These risks and other additional factors affecting Orchid`s business are discussed in the "Risk Factors" sections of Orchid`s Annual Report on Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. Orchid expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Orchid`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

SOURCE Orchid BioSciences, Inc.


CONTACT: Tracy J. Henrikson, Director, Corporate Communications, Orchid
BioSciences, [phone]

URL: http://www.orchid.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: New Jersey
INDUSTRY KEYWORD: BIO
MTC
HEA


STOCK SYMBOLS: [(orch)]

JS200

[js200]

[js200]

VOLUME(-): ORCH Volume 67% > 20-adsv, Stock -5.77%

Monday , May 05, 2003 14:46 ET

This is the 3rd VOLUME alert for ORCH in the past 7 calendar days.

Trading for Orchid BioSciences Inc (NASDAQ NM: ORCH) has been heavier than usual in today`s session. By 14:45 ET, the stock had already traded 531,400 shares via 249 trades. The cumulative volume is 66.59% above its 20-day average of 318,987. Normally the stock experiences around 175 individual trades per session.

So far, today`s volume surge has caused a net decline in ORCH`s stock price. At the time of this alert, the stock was trading at $0.490, down $-0.030 (-5.77%).

One year ago, the Company`s shares closed at $2.120. The price has declined more than 76 percent since then.

Over the last 10 trading session ORCH has traded in a range between $0.360 and $0.620 and is currently trading 79.50% below its 52-week high of $2.390 set on May 09, 2002 and 48.48% above its 52-week low of $0.330 from March 26, 2003.

In the previous 3 sessions, ORCH trading has displayed a mixed trend. Closing results have been as follows:

May 02, 2003 --- closed at $0.520 even for the day on 376,200 shares
May 01, 2003 --- closed at $0.520 down $0.080 (-13.33%) on 867,500 shares
April 30, 2003 --- closed at $0.600 up $0.170 (+39.53%) on 1,607,300 shares

The Company last released news on May 02, 2003:

"Orchid BioSciences to Host Conference Call to Announce First Quarter 2003 Financial Results"

ORCHID BIOSCIENCES INC
Orchid Biosciences, Inc. develops and commercializes genetic diversity technologies, products, and services. Genetic diversity information is used to facilitate the development and effectiveness of drugs and increase the success of tissue transplants. Genetic diversity products also have other commercial applications outside of the healthcare field, including forensics, paternity and other identity testing, and for improved crop development and for livestock breeding programs.

JS200

[suncomesout]

Na, also: Endlich ist Licht am Ende des Tunnels!

ORCHID RECEIVES FIRST APPROVAL TO USE SNP TECHNOLOGY AS PRIMARY MARKERS FOR PATERNITY TESTING




PRINCETON, N.J., May 7, 2003 - Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced that it is the first company to receive approval from the American Association of Blood Banks (AABB) to use single nucleotide polymorphisms (SNPs) as stand-alone genetic markers in its Orchid GeneScreen paternity testing operations. Orchid is replacing conventional short tandem repeat, or STR techniques with more cost-effective methods that use its SNP genotyping technology to achieve additional efficiencies and further improve quality and service in its paternity testing operations. The AABB is the leading standard-setting organization for parentage testing in the U.S.

Orchid expects the application of its technology to result in decreased per-test cost, enhanced gross margins and increased volume capacity in its Orchid GeneScreen business. With the approval of the AABB, Orchid is deploying its SNP technology on its ultra high throughput platform throughout its U.S. paternity testing laboratory operations, and anticipates the technology will be fully implemented before the end of the year.

“The AABB’s approval of use of Orchid’s cutting-edge SNP genotyping technology marks another milestone in Orchid GeneScreen’s track record of leadership and innovation in paternity testing,” said Keith W. Brown, senior vice president of Orchid BioSciences and General Manager of Orchid Identity Genomics.

“We expect use of SNP technology to enable us to achieve greater operating efficiencies and reduce costs,” said Andrew P. Savadelis, senior vice president and chief financial officer of Orchid BioSciences. “We also expect that it will allow us to grow without having to expand our laboratory facilities, an important asset as we continue to build our market share in the high-growth, high-margin private paternity testing sector.”

Orchid GeneScreen, the paternity testing business of Orchid BioSciences, Inc., is one of the largest paternity testing providers in the world. Orchid GeneScreen provides DNA testing services for both governmental agency and private customers to determine the parentage of a child. The AABB provides for the assessment and accreditation of laboratories conducting parentage testing, in addition to publishing guidelines for laboratories that perform DNA testing to identify and confirm paternity.

Orchid BioSciences is already using its SNP technology in its public health disease susceptibility testing and in forensic DNA testing for analyzing degraded samples, and it also is applying it in its pharmacogenetics-based personalize medicine initiative.






Suncomesout